Our results, in combination with previously published data describing FGF/R and ALK/EML4 interactions, might be the starting point for further investigations on the exact pathomechanisms of acquired TKI resistance in ESCC treatment. This evidence concerns the gene EML4 and esophageal squamous cell carcinoma.